Skip to main content
. 2016 Jun 10;18:135. doi: 10.1186/s13075-016-1020-3

Fig. 4.

Fig. 4

Impact of varying model inputs on incremental cost-effectiveness ratio for an add-on B-cell test or magnetic resonance imaging (MRI) in intermediate-risk patients. QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio, FP false positive